The stock of small-cap biotech Wave Life Sciences Inc. soared 51% Tuesday after the company reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder Duchenne ...
Wave Life Sciences (WVE) announced positive results from its phase 1b/2a RestorAAtion-2 study using WVE-006 for the treatment of patients with alpha-1 antitrypsin deficiency [AATD]. It was shown that ...
Wave Life Sciences (WVE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on November 12. Analyst Joseph Schwartz from Leerink Partners reiterated a Buy rating ...
Atai Life Sciences and Beckley Psytech announced positive results from a Phase 2b clinical trial evaluating BPL-003, a treatment for treatment-resistant depression (TRD). The study achieved its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results